Reuters logo
Achillion's hepatitis C drug cures all patients in mid-stage trial
August 15, 2014 / 12:10 PM / 3 years ago

Achillion's hepatitis C drug cures all patients in mid-stage trial

Aug 15 (Reuters) - Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.

The mid-stage trial tested Achillion’s drug, ACH-3102, in 12 patients in combination with Gilead Sciences Inc’s Sovaldi, also known as sofosbuvir.

Achillion said it would begin treating 12 additional patients for six weeks with a once-daily dose of ACH-3102 and sofosbuvir.

The trial excluded the older hepatitis C drug ribavirin, which can cause rashes, anemia and other side effects.

Achillion shares rose about 10 percent to $9.25 in premarket trading. (Reporting by Anand Basu in Bangalore; Editing by Simon Jennings)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below